Sinovac Biotech LtdFind Ratings Reports
SINOVAC BIOTECH LTD's gross profit margin for the third quarter of its fiscal year 2016 has increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. SINOVAC BIOTECH LTD has strong liquidity. Currently, the Quick Ratio is 1.55 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 7.07% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||28.74||16.76|
|Net Income ($mil)||3.21||-1.6|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||54.63||54.36|
|Total Assets ($mil)||203.72||204.33|
|Total Debt ($mil)||37.79||28.25|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||84.61||77.09|
|Return on Assets||-2.22||-0.13|
|Return on Equity||-5.88||0.27|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||56.91||57.0|
|Div / share||0.0||0.0|
|Book value / share||2.02||2.17|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||51756.0||90029.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 3.02 indicates valuation on par with the S&P 500 average of 2.82 and a significant discount versus the industry average of 11.06. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SINOVAC BIOTECH LTD proves to trade at a discount to investment alternatives within the industry.
|SVA NM||Peers 33.44||SVA NM||Peers 25.93|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SVA's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SVA's P/CF is negative making the measure meaningless.
|SVA NA||Peers 23.71||SVA NA||Peers 0.41|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SVA 3.02||Peers 11.06||SVA -1100.00||Peers 3.13|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SVA is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, SVA is expected to significantly trail its peers on the basis of its earnings growth rate.
|SVA 5.42||Peers 151.50||SVA -1.18||Peers 514.21|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SVA is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
SVA significantly trails its peers on the basis of sales growth